ARCA biopharma.

ARCA biopharma, Medtronic to study efficiency of Gencaro for prevention of atrial fibrillation ARCA biopharma, Inc . , a biopharmaceutical business developing genetically-targeted treatments for cardiovascular diseases, announced that it has entered into an contract with Medtronic today, Inc. , a leader in medical technology to improve the treatment of chronic illnesses, including cardiac rhythm disorders, to collaborate on ARCA's proposed clinical trial, referred to as GENETIC-AF, of its lead developmental medication Gencaro . GENETIC-AF is planned as a Stage 2b/3 clinical trial comparing Gencaro to metoprolol CR/XL for avoidance of atrial fibrillation in patients with center failure and reduced remaining ventricular ejection fraction .

THE BUSINESS intends to utilize the net proceeds of this financing for analysis and development, working capital and general corporate purposes. Before April 21 The providing will close on or, 2011. Roth Capital Companions acted as positioning agent for the offering.. ARCA biopharma to market $3 million of common stock and warrants in registered direct offering ARCA biopharma, Inc. , a biopharmaceutical business developing genetically-targeted treatments for atrial fibrillation, center failure and additional cardiovascular illnesses, today announced that it has agreed to sell approximately $3 million of its common share and warrants to institutional investors in a registered direct offering. ARCA will concern an aggregate of around 1. 68 million shares of common stock to investors together with warrants to purchase approximately 1.18 million shares of common stock.